Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.
The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.
One of Deepbridge's Technology Growth EIS Companies HeadBox, has finalised a £2 million fundraise led by Deepbridge Capital. This round has taken the total funding to £13.2 million.
Fund Her North has facilitated investment into six female led businesses worth over £4.2m in its first year, since it was established in October 2020.
One of Deepbridge Capital's Technology Growth EIS Companies, Hurricane Modular Commerce Limited, has been named 'Supplier of the Year' at this year’s Parcel & Post Technology International Awards.
One of Deepbridge Capital's Life Science EIS companies, Liverpool Chirochem Ltd., has announced the collaboration with Eurofins Discovery, a provider of products and services to the drug discovery industry.
Deepbridge Capital has now exceeded £200 million of funds deployed across is EIS and Estate Planning Service funds, with a current Net Asset Value (NAV) of over £250 million.
Deepbridge Capital has, to date, invested in 71 companies across the UK with Enterprise Investment Scheme (EIS) funding, a further 63 companies at the Seed EIS stage, with three profitable exits. Deepbridge Capital launched its first EIS Fund in the 2013/14 tax year specialising in providing venture capital to early-stage technology, life sciences and renewable energy companies.
Deepbridge is pleased to announce that we have been awarded the ‘Spirit of EIS’ Award at the 2021 EISA Awards, which took place in The Cholmondeley Room at The House of Lords on the 7th October.
